Arcus Biosciences, Inc. Debt Securities, Available-for-sale, Realized Gain (Loss)
Arcus Biosciences, Inc. (RCUS) reported Debt Securities, Available-for-sale, Realized Gain (Loss) of $300.00 thousand for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-02.
Discontinued › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss · last filed 2022-11-02
- Arcus Biosciences, Inc. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2022-09-30 was $300.00K.
- Arcus Biosciences, Inc. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2022-06-30 was $0.00.
- Arcus Biosciences, Inc. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2022-03-31 was $0.00.
- Arcus Biosciences, Inc. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2021-12-31 was $0.00.
- Arcus Biosciences, Inc. debt securities, available-for-sale, realized gain (loss) for fiscal 2020 was $0.00.
- Arcus Biosciences, Inc. debt securities, available-for-sale, realized gain (loss) for fiscal 2019 was $0.00.
| Period end | Debt Securities, Available-for-sale, Realized Gain (Loss) 3 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 6 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 9 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2022-09-30 | $300.00K 10-Q · filed 2022-11-02 | $300.00K derived: sum of 2 quarters · filed 2022-11-02 | $300.00K 10-Q · filed 2022-11-02 | $300.00K derived: sum of 4 quarters · filed 2022-11-02 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $0.00 10-Q · filed 2022-08-03 | $0.00 derived: sum of 3 quarters · filed 2022-08-03 | $0.00 derived: sum of 4 quarters · filed 2022-11-02 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-09 | $0.00 derived: sum of 2 quarters · filed 2022-08-03 | $0.00 derived: sum of 3 quarters · filed 2022-11-02 | |
| 2021-12-31 | $0.00 derived: 10-Q 12 month − 10-Q 9 month · filed 2022-08-03 | $0.00 derived: sum of 2 quarters · filed 2022-11-02 | $0.00 10-Q · filed 2022-08-03 | |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-02 | $0.00 10-Q · filed 2022-11-02 | ||
| 2020-12-31 | $0.00 10-K · filed 2022-02-23 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |